LifeSci Capital Initiates Coverage On Protara Therapeutics with Outperform Rating, Announces Price Target of $22

Benzinga · 03/11/2025 12:36
LifeSci Capital initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Outperform rating and announces Price Target of $22.